Sage Readies Zurzuvae For December Launch With Slow Ramp As Payer Talks Progress
No Update On Plans For MDD Resubmission
Sage and Biogen set a $15,900 list price for Zurzuvae, the 14-day postpartum depression drug approved in the US in August, and expect broad access but formulary discussions will continue into 2024.
